Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries.
- Published in:
- 2004
- By:
- Publication type:
- commentary
Works by Scheen, Andre
Results: 127
1
2
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
- Published in:
- 2017
- By:
- Publication type:
- journal article
3
Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
4
Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
- Published in:
- 2007
- By:
- Publication type:
- journal article
5
Pharmacokinetic interactions with thiazolidinediones.
- Published in:
- 2007
- By:
- Publication type:
- journal article
6
Drug interactions of clinical importance with antihyperglycaemic agents: an update.
- Published in:
- 2005
- By:
- Publication type:
- journal article
7
Hepatic Insulin Resistance in Obese Non-Diabetic Subjects and in Type 2 Diabetic Patients.
- Published in:
- Obesity (19307381), 2002, v. 10, n. 3, p. 129, doi. 10.1038/oby.2002.21
- By:
- Publication type:
- Article
8
Glucose-lowering agents and risk of cardiac arrhythmias.
- Published in:
- Acta Cardiologica, 2023, v. 78, n. 3, p. 377, doi. 10.1080/00015385.2022.2101875
- By:
- Publication type:
- Article
9
Association Between the ACE Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes.
- Published in:
- 2022
- By:
- Publication type:
- journal article
10
I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes.
- Published in:
- 2021
- By:
- Publication type:
- journal article
11
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
- Published in:
- 2018
- By:
- Publication type:
- journal article
12
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment.
- Published in:
- Diabetes Care, 2015, v. 38, n. 6, p. 1161, doi. 10.2337/dc14-1630
- By:
- Publication type:
- Article
13
Poor Glycemic Control Is a Major Factor in the Overestimation of Glomerular Filtration Rate in Diabetic Patients. Diabetes Care 2014;37:596-603.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
14
Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2004, v. 20, n. 3, p. 178, doi. 10.1002/dmrr.447
- By:
- Publication type:
- Article
15
Antiobesity pharmacotherapy in the management of type 2 diabetes.
- Published in:
- 2000
- By:
- Publication type:
- journal article
16
Facing up to the imperceptible perspiration. Modulatory influences by diabetic neuropathy, physical exercise and antiperspirant.
- Published in:
- Skin Research & Technology, 2011, v. 17, n. 4, p. 487, doi. 10.1111/j.1600-0846.2011.00523.x
- By:
- Publication type:
- Article
17
Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System.
- Published in:
- Drugs, 2004, v. 64, n. 22, p. 2537, doi. 10.2165/00003495-200464220-00004
- By:
- Publication type:
- Article
18
Current Management Strategies for Coexisting Diabetes Mellitus and Obesity.
- Published in:
- Drugs, 2003, v. 63, n. 12, p. 1165, doi. 10.2165/00003495-200363120-00001
- By:
- Publication type:
- Article
19
Is There a Role for α-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?
- Published in:
- Drugs, 2003, v. 63, n. 10, p. 933, doi. 10.2165/00003495-200363100-00002
- By:
- Publication type:
- Article
20
Diabetes and Ramadan’s fasting: patients’ and health professionals’ representations and practice.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
21
Diabète et jeüne de Ramadan : représentations et pratiques de patients et de professionnels de santé.
- Published in:
- Therapeutic Patient Education / Éducation Thérapeutique du Patient, 2013, v. 5, n. 2, p. 199, doi. 10.1051/tpe/2013031
- By:
- Publication type:
- Article
22
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.
- Published in:
- Bipolar Disorders, 2008, v. 10, n. 2, p. 342, doi. 10.1111/j.1399-5618.2007.00520.x
- By:
- Publication type:
- Article
23
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.
- Published in:
- Current Cardiology Reports, 2019, v. 21, n. 8, p. N.PAG, doi. 10.1007/s11886-019-1165-1
- By:
- Publication type:
- Article
24
Greater efficacy of pulsatile insulin in type I diabetics critically depends on plasma glucagon levels.
- Published in:
- 1987
- By:
- Publication type:
- journal article
25
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.
- Published in:
- Drugs, 2024, v. 84, n. 11, p. 1347, doi. 10.1007/s40265-024-02090-9
- By:
- Publication type:
- Article
26
Canagliflozin: A Review in Type 2 Diabetes.
- Published in:
- Drugs, 2017, v. 77, n. 14, p. 1577, doi. 10.1007/s40265-017-0801-6
- By:
- Publication type:
- Article
27
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
28
The skin landscape in diabetes mellitus. Focus on dermocosmetic management.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2013, v. 6, p. 127, doi. 10.2147/CCID.S43141
- By:
- Publication type:
- Article
29
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
- Published in:
- Expert Review of Clinical Pharmacology, 2023, v. 16, n. 11, p. 1053, doi. 10.1080/17512433.2023.2279193
- By:
- Publication type:
- Article
30
Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
- Published in:
- Expert Review of Clinical Pharmacology, 2017, v. 10, n. 12, p. 1303, doi. 10.1080/17512433.2017.1389645
- By:
- Publication type:
- Article
31
Pharmacological management of type 2 diabetes: what’s new in 2017?
- Published in:
- Expert Review of Clinical Pharmacology, 2017, v. 10, n. 12, p. 1383, doi. 10.1080/17512433.2017.1376652
- By:
- Publication type:
- Article
32
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
- Published in:
- Expert Review of Clinical Pharmacology, 2016, v. 9, n. 3, p. 385, doi. 10.1586/17512433.2016.1141046
- By:
- Publication type:
- Article
33
Effect of brivaracetam on CYP3A activity, measured by oral midazolam.
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, n. 5, p. 543, doi. 10.1002/jcph.446
- By:
- Publication type:
- Article
34
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.
- Published in:
- Expert Opinion on Drug Safety, 2024, v. 23, n. 7, p. 797, doi. 10.1080/14740338.2024.2354885
- By:
- Publication type:
- Article
35
Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
- Published in:
- Expert Opinion on Drug Safety, 2020, v. 19, n. 3, p. 243, doi. 10.1080/14740338.2020.1733967
- By:
- Publication type:
- Article
36
An update on the safety of SGLT2 inhibitors.
- Published in:
- Expert Opinion on Drug Safety, 2019, v. 18, n. 4, p. 295, doi. 10.1080/14740338.2019.1602116
- By:
- Publication type:
- Article
37
The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
- Published in:
- Expert Opinion on Drug Safety, 2018, v. 17, n. 8, p. 837, doi. 10.1080/14740338.2018.1497159
- By:
- Publication type:
- Article
38
The safety of gliptins : updated data in 2018.
- Published in:
- Expert Opinion on Drug Safety, 2018, v. 17, n. 4, p. 387, doi. 10.1080/14740338.2018.1444027
- By:
- Publication type:
- Article
39
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update.
- Published in:
- Expert Opinion on Drug Metabolism & Toxicology, 2023, v. 19, n. 8, p. 543, doi. 10.1080/17425255.2023.2252333
- By:
- Publication type:
- Article
40
Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties.
- Published in:
- Expert Opinion on Drug Metabolism & Toxicology, 2022, v. 18, n. 6, p. 381, doi. 10.1080/17425255.2022.2105693
- By:
- Publication type:
- Article
41
Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.
- Published in:
- Expert Opinion on Drug Metabolism & Toxicology, 2017, v. 13, n. 5, p. 583, doi. 10.1080/17425255.2017.1315102
- By:
- Publication type:
- Article
42
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
- Published in:
- Expert Opinion on Drug Metabolism & Toxicology, 2016, v. 12, n. 12, p. 1407, doi. 10.1080/17425255.2016.1215427
- By:
- Publication type:
- Article
43
Sibutramine on cardiovascular outcome.
- Published in:
- 2011
- By:
- Publication type:
- journal article
44
Sibutramine on Cardiovascular Outcome.
- Published in:
- Diabetes Care, 2011, v. 34, p. S114, doi. 10.2337/dc11-s205
- By:
- Publication type:
- Article
45
Pulsatile Stress in Middle-Aged Patients With Type 1 or Type 2 Diabetes Compared With Nondiabetic Control Subjects.
- Published in:
- Diabetes Care, 2010, v. 33, n. 11, p. 2424, doi. 10.2337/dc10-0302
- By:
- Publication type:
- Article
46
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
- Published in:
- 2008
- By:
- Publication type:
- journal article
47
Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients.
- Published in:
- Diabetes Care, 2008, v. 31, p. S229, doi. 10.2337/dc08-s258
- By:
- Publication type:
- Article
48
Squatting Amplifies Pulse Pressure Increase With Disease Duration in Patients With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2008, v. 31, n. 2, p. 322, doi. 10.2337/dc07-1646
- By:
- Publication type:
- Article
49
Reversibility of Antipsychotic Treatment-Related Diabetes in Patients With Schizophrenia.
- Published in:
- 2006
- By:
- Publication type:
- Letter
50
Preventing, Delaying, or Masking Type 2 Diabetes With Metformin in the Diabetes Prevention Program.
- Published in:
- Diabetes Care, 2003, v. 26, n. 9, p. 2701, doi. 10.2337/diacare.26.9.2701
- By:
- Publication type:
- Article